Loading news...
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, up 605% YoY, driven by MIPLYFFA, and is nearing profitability. ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 is projected as the first year of true profitability, with analyst EPS estimates between $0.29 and $1.07 and revenue growth driven by MIPLYFFA.
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Journey Medical (NASDAQ: DERM - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Zevra Therapeutics and
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 53,000 shares of the Company's common stock (the “Inducement Awards”) to three new employees pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).
CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alicia Secor to the Company's Board of Directors (Board). The Company also announced the retirement of director Wendy Dixon, PhD, effective today.
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities.
Shares of Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on
Zevra Therapeutics, Inc. ( ZVRA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate Communications Neil McFarlane - President, CEO & Director Joshua Schafer - Chief Commercial Officer R. Clifton - CFO & Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Samantha Corwin - William Blair & Company L.L.C.
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.69 per share a year ago.
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CELEBRATION, Fla.
CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET.
- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 - Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company's common stock (the “Inducement Awards”) to two new employees pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).
Zevra Therapeutics (ZVRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients
New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-6, 2025, in Kyoto, Japan.